Edition:
United States

CTi Biopharma Corp (CTIC.OQ)

CTIC.OQ on NASDAQ Stock Exchange Capital Market

0.49USD
2 Dec 2016
Change (% chg)

-- (--)
Prev Close
$0.49
Open
--
Day's High
--
Day's Low
--
Volume
3,400
Avg. Vol
140,406
52-wk High
$1.34
52-wk Low
$0.25

CTIC.OQ

Chart for CTIC.OQ

About

CTI BioPharma Corp. (CTI) is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for... (more)

Overall

Beta: 0.88
Market Cap(Mil.): $112.98
Shares Outstanding(Mil.): 282.38
Dividend: --
Yield (%): --

Financials

  CTIC.OQ Industry Sector
P/E (TTM): -- 42.21 29.87
EPS (TTM): -0.29 -- --
ROI: -217.95 -1.09 14.95
ROE: -- -2.39 16.29

BRIEF-CTi Biopharma announces phase 3 data from the PERSIST-2 trial of Pacritinib to be presented in late-breaking session at ASH annual meeting

* CTi Biopharma announces phase 3 data from the PERSIST-2 trial of Pacritinib to be presented in late-breaking session at ASH annual meeting Source text for Eikon: Further company coverage:

Nov 21 2016

BRIEF-CTI Biopharma reports Q3 loss per share $0.10

* Total revenues for Q3 were $4.4 million compared to $1.0 million

Nov 08 2016

BRIEF-CTI BioPharma announces retirement of president and CEO

* James Bianco,CTI BioPharma's president and chief executive officer, has retired from company

Oct 03 2016

BRIEF-CTi biopharma granted 180 day extension by NASDAQ to regain compliance

* CTi Biopharma granted 180 day extension by NASDAQ to regain compliance with minimum bid price rule

Sep 22 2016

BRIEF-CTI Biopharma announces top-line results from PERSIST-2 phase 3 trial of Pacritinib for high-risk patients with advanced Myelofibrosis

* CTI Biopharma announces top-line results from persist-2 phase 3 trial of pacritinib for high-risk patients with advanced myelofibrosis

Aug 29 2016

BRIEF-CTI Biopharma Q2 loss per share $0.07

* CTI Biopharma reports second quarter 2016 financial results

Aug 04 2016

Earnings vs. Estimates